Α-synuclein misfolding and Parkinson's disease.
暂无分享,去创建一个
[1] Min Zhu,et al. The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils. , 2004, The Journal of biological chemistry.
[2] V. Uversky,et al. Methionine oxidation inhibits fibrillation of human α‐synuclein in vitro , 2002 .
[3] E. Richfield,et al. Chronic exposure to manganese decreases striatal dopamine turnover in human alpha-synuclein transgenic mice , 2011, Neuroscience.
[4] D. Allsop,et al. Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease. , 2002, Free radical biology & medicine.
[5] K. Chung,et al. Induction of Neuronal Cell Death by Rab5A-dependent Endocytosis of α-Synuclein* , 2001, The Journal of Biological Chemistry.
[6] V. Uversky,et al. Methionine oxidation stabilizes non-toxic oligomers of alpha-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions. , 2010, Biochimica et biophysica acta.
[7] V. Buchman,et al. Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease , 2003, Neuropharmacology.
[8] D. Raleigh,et al. A critical assessment of the role of helical intermediates in amyloid formation by natively unfolded proteins and polypeptides. , 2009, Protein engineering, design & selection : PEDS.
[9] B. Ghetti,et al. Ubiquitination of α-Synuclein in Lewy Bodies Is a Pathological Event Not Associated with Impairment of Proteasome Function* , 2003, Journal of Biological Chemistry.
[10] D. A. Monte. The role of environmental agents in Parkinson's disease , 2001, Clinical Neuroscience Research.
[11] Adam Douglass,et al. Mechanism of Prion Propagation: Amyloid Growth Occurs by Monomer Addition , 2004, PLoS biology.
[12] Karen A. Lewis,et al. A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. , 2005, The Journal of biological chemistry.
[13] R. Perrin,et al. Interaction of Human α-Synuclein and Parkinson's Disease Variants with Phospholipids , 2000, The Journal of Biological Chemistry.
[14] M. Feany,et al. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. , 2005, Nature neuroscience.
[15] B. Hyman,et al. Heat‐shock protein 70 modulates toxic extracellular α‐synuclein oligomers and rescues trans‐synaptic toxicity , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[16] J. Dordick,et al. Resveratrol Selectively Remodels Soluble Oligomers and Fibrils of Amyloid Aβ into Off-pathway Conformers* , 2010, The Journal of Biological Chemistry.
[17] H. Lashuel,et al. Dissecting the mechanisms of tissue transglutaminase-induced cross-linking of alpha-synuclein: implications for the pathogenesis of Parkinson disease. , 2009, The Journal of biological chemistry.
[18] B. Hyman,et al. Converse modulation of toxic alpha-synuclein oligomers in living cells by N'-benzylidene-benzohydrazide derivates and ferric iron. , 2010, Biochemical and biophysical research communications.
[19] J. Winderickx,et al. Phosphorylation, lipid raft interaction and traffic of alpha-synuclein in a yeast model for Parkinson. , 2008, Biochimica et biophysica acta.
[20] M. Kataoka,et al. X-ray solution scattering studies of protein folding. , 1996, Folding & design.
[21] V. Uversky,et al. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. , 2001, Biochemistry.
[22] I. Ziv,et al. Mutant and wild-type α-synuclein interact with mitochondrial cytochrome C oxidase , 2002, Journal of Molecular Neuroscience.
[23] Vladimir N. Uversky,et al. Neuropathology, biochemistry, and biophysics of α‐synuclein aggregation , 2007 .
[24] R. Bradshaw,et al. Protein translocation and turnover in eukaryotic cells. , 1989, Trends in biochemical sciences.
[25] M. Zigmond,et al. A Role for α-Synuclein in the Regulation of Dopamine Biosynthesis , 2002, The Journal of Neuroscience.
[26] B. E. Staveley,et al. parkin counteracts symptoms in a Drosophila model of Parkinson's disease , 2004, BMC Neuroscience.
[27] A. Kanthasamy,et al. Wild-type α-synuclein interacts with pro-apoptotic proteins PKCδ and BAD to protect dopaminergic neuronal cells against MPP+-induced apoptotic cell death , 2005 .
[28] V. Uversky,et al. Nuclear localization of alpha-synuclein and its interaction with histones. , 2003, Biochemistry.
[29] Y. Sung,et al. alpha-Synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells. , 2002, The Journal of biological chemistry.
[30] A. Minton,et al. The Influence of Macromolecular Crowding and Macromolecular Confinement on Biochemical Reactions in Physiological Media* , 2001, The Journal of Biological Chemistry.
[31] S. Paik,et al. Copper ( II )-induced self-oligomerization of α-synuclein , 1999 .
[32] R. Barbour,et al. Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease* , 2006, Journal of Biological Chemistry.
[33] R. Lerner,et al. Small molecule oxidation products trigger disease-associated protein misfolding. , 2006, Accounts of chemical research.
[34] P. Walsh. Baicalin is a Major Component of PC-SPES Which Inhibits the Proliferation of Human Cancer Cells Via Apoptosis and Cell Cycle Arrest , 2002 .
[35] S. Lindquist,et al. Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. , 2008, The Journal of clinical investigation.
[36] D. Ehrnhoefer,et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers , 2008, Nature Structural &Molecular Biology.
[37] V. Uversky,et al. Anion-induced folding of Staphylococcal nuclease: characterization of multiple equilibrium partially folded intermediates. , 1998, Journal of molecular biology.
[38] B. Diwan,et al. Potential role of alpha-synuclein and metallothionein in lead-induced inclusion body formation. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.
[39] Dirar Homouz,et al. Structure, function, and folding of phosphoglycerate kinase are strongly perturbed by macromolecular crowding , 2010, Proceedings of the National Academy of Sciences.
[40] Rodrigo Morales,et al. Molecular Cross Talk between Misfolded Proteins in Animal Models of Alzheimer's and Prion Diseases , 2010, The Journal of Neuroscience.
[41] M. E. Clark,et al. Living with water stress: evolution of osmolyte systems. , 1982, Science.
[42] M. Brin,et al. TorsinA accumulation in Lewy bodies in sporadic Parkinson’s disease , 2000, Brain Research.
[43] H. Erdjument-Bromage,et al. Parkinson's disease-associated alpha-synuclein is a calmodulin substrate. , 2003, The Journal of biological chemistry.
[44] R. Szargel,et al. Monoubiquitylation of α-Synuclein by Seven in Absentia Homolog (SIAH) Promotes Its Aggregation in Dopaminergic Cells* , 2008, Journal of Biological Chemistry.
[45] R A Crowther,et al. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[46] J. Dordick,et al. Aromatic Small Molecules Remodel Toxic Soluble Oligomers of Amyloid β through Three Independent Pathways* , 2010, The Journal of Biological Chemistry.
[47] F. Checler,et al. Wild-type but Not Parkinson's Disease-related Ala-53 → Thr Mutant α-Synuclein Protects Neuronal Cells from Apoptotic Stimuli* , 2000, The Journal of Biological Chemistry.
[48] L. Serpell,et al. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[49] P. Jensen,et al. Pathogenic effects of alpha-synuclein aggregation. , 2005, Brain research. Molecular brain research.
[50] A. Minton. Implications of macromolecular crowding for protein assembly. , 2000, Current opinion in structural biology.
[51] P. Lansbury. Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[52] Kazuyuki Takata,et al. Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4‐phenylbutyrate, a chemical chaperone , 2007, Journal of neurochemistry.
[53] John B. Shoven,et al. I , Edinburgh Medical and Surgical Journal.
[54] H. Lashuel,et al. E46K Parkinson's-linked mutation enhances C-terminal-to-N-terminal contacts in alpha-synuclein. , 2009, Journal of molecular biology.
[55] V. Uversky,et al. Characterization of the non-fibrillar α-synuclein oligomers. , 2011, Protein and peptide letters.
[56] Sachiko Takahama,et al. Magnesium deficiency over generations in rats with special references to the pathogenesis of the parkinsonism–dementia complex and amyotrophic lateral sclerosis of Guam , 2006, Neuropathology : official journal of the Japanese Society of Neuropathology.
[57] Nutan Sharma,et al. TorsinA and heat shock proteins act as molecular chaperones: suppression of α‐synuclein aggregation , 2002, Journal of neurochemistry.
[58] Vladimir N Uversky,et al. Multiple aromatic side chains within a disordered structure are critical for transcription and transforming activity of EWS family oncoproteins , 2007, Proceedings of the National Academy of Sciences.
[59] S. Radford,et al. A generic mechanism of beta2-microglobulin amyloid assembly at neutral pH involving a specific proline switch. , 2009, Journal of molecular biology.
[60] Min Zhu,et al. Alpha-synuclein can function as an antioxidant preventing oxidation of unsaturated lipid in vesicles. , 2006, Biochemistry.
[61] Jennifer C. Lee,et al. Effect of dioxygen on copper(II) binding to alpha-synuclein. , 2010, Journal of inorganic biochemistry.
[62] C. Marsden,et al. Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease , 1989, Journal of neurochemistry.
[63] V. Uversky,et al. Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro. , 2002, FEBS letters.
[64] V. Uversky,et al. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. , 2001, The Journal of biological chemistry.
[65] J. Ridet,et al. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[66] C. Masters,et al. The structure of dopamine induced α-synuclein oligomers , 2010, European Biophysics Journal.
[67] Gerald F. Tremblay. Neuropathology , 1989, Neurology.
[68] M. Goedert. Parkinson's disease and other alpha-synucleinopathies. , 2001, Clinical chemistry and laboratory medicine.
[69] Gregory G. Brown,et al. Occupational exposures to metals as risk factors for Parkinson's disease , 1997, Neurology.
[70] A. Jonas,et al. Stabilization of α-Synuclein Secondary Structure upon Binding to Synthetic Membranes* , 1998, The Journal of Biological Chemistry.
[71] M. Citron,et al. alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. , 1999, The Journal of biological chemistry.
[72] A. Fink,et al. Acid-induced folding of proteins. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[73] Miss A.O. Penney. (b) , 1974, The New Yale Book of Quotations.
[74] Zheng Rong Yang,et al. RONN: the bio-basis function neural network technique applied to the detection of natively disordered regions in proteins , 2005, Bioinform..
[75] C. Glabe,et al. Structural Classification of Toxic Amyloid Oligomers* , 2008, Journal of Biological Chemistry.
[76] C. Ross,et al. Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. , 2005, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[77] G C COTZIAS,et al. Manganese in health and disease. , 1958, Physiological reviews.
[78] E. Lattman. Small angle scattering studies of protein folding , 1994 .
[79] Songsong Cao,et al. Torsin-Mediated Protection from Cellular Stress in the Dopaminergic Neurons of Caenorhabditis elegans , 2005, The Journal of Neuroscience.
[80] J. Kenney,et al. Microtubule-associated Protein 1B Is a Component of Cortical Lewy Bodies and Binds α-Synuclein Filaments* , 2000, The Journal of Biological Chemistry.
[81] Ralf Langen,et al. Structure of membrane-bound α-synuclein from site-directed spin labeling and computational refinement , 2008, Proceedings of the National Academy of Sciences.
[82] Matthew J. Farrer,et al. Comparison of kindreds with parkinsonism and α‐synuclein genomic multiplications , 2004 .
[83] David Eisenberg,et al. Atomic structures of amyloid cross-beta spines reveal varied steric zippers. , 2007, Nature.
[84] R. He,et al. Ribosylation Rapidly Induces α-Synuclein to Form Highly Cytotoxic Molten Globules of Advanced Glycation End Products , 2010, PloS one.
[85] Ad Bax,et al. Structure and Dynamics of Micelle-bound Human α-Synuclein* , 2005, Journal of Biological Chemistry.
[86] M. Bennett. The role of α-synuclein in neurodegenerative diseases , 2005 .
[87] Daphne H. E. W. Huberts,et al. Macromolecular Crowding Compacts Unfolded Apoflavodoxin and Causes Severe Aggregation of the Off-pathway Intermediate during Apoflavodoxin Folding* , 2008, Journal of Biological Chemistry.
[88] C. Ross,et al. α-Synuclein Phosphorylation Enhances Eosinophilic Cytoplasmic Inclusion Formation in SH-SY5Y Cells , 2005, The Journal of Neuroscience.
[89] P. Lansbury,et al. The UCH-L1 Gene Encodes Two Opposing Enzymatic Activities that Affect α-Synuclein Degradation and Parkinson's Disease Susceptibility , 2002, Cell.
[90] Elizabeth Head,et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers , 2007, Molecular Neurodegeneration.
[91] John S Lazo,et al. Low molecular weight inhibitors of Myc–Max interaction and function , 2003, Oncogene.
[92] S. Dudek,et al. Transglutaminase Catalyzes the Formation of Sodium Dodecyl Sulfate‐Insoluble, Alz‐50‐Reactive Polymers of τ , 1993, Journal of neurochemistry.
[93] P. Radivojac,et al. PROTEINS: Structure, Function, and Bioinformatics Suppl 7:176–182 (2005) Exploiting Heterogeneous Sequence Properties Improves Prediction of Protein Disorder , 2022 .
[94] H. Fukuyama,et al. Dietary intake of metals and risk of Parkinson's disease: A case-control study in Japan , 2011, Journal of the Neurological Sciences.
[95] G. Sancesario,et al. Metal changes in CSF and peripheral compartments of parkinsonian patients , 2006, Journal of the Neurological Sciences.
[96] H. Erdjument-Bromage,et al. Parkinson's Disease-associated α-Synuclein Is a Calmodulin Substrate* , 2003, The Journal of Biological Chemistry.
[97] M. Bennett. The role of alpha-synuclein in neurodegenerative diseases. , 2005, Pharmacology & therapeutics.
[98] Marco Brucale,et al. Conformational equilibria in monomeric alpha-synuclein at the single molecule level , 2007, 0712.1973.
[99] Seung-Jae Lee,et al. Membrane-bound α-Synuclein Has a High Aggregation Propensity and the Ability to Seed the Aggregation of the Cytosolic Form* , 2002, The Journal of Biological Chemistry.
[100] T. Iwatsubo,et al. Small Molecule Inhibitors of α-Synuclein Filament Assembly† , 2006 .
[101] Vladimir N. Uversky,et al. Neurotoxicant-induced animal models of Parkinson’s disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration , 2004, Cell and Tissue Research.
[102] J R Ghilardi,et al. Alzheimer's disease amyloid propagation by a template-dependent dock-lock mechanism. , 2000, Biochemistry.
[103] R. Jakes,et al. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of α‐synuclein protein implicated in Parkinson's disease , 1998, FEBS letters.
[104] V. Uversky,et al. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. , 2002, The Journal of biological chemistry.
[105] H. Band,et al. Tau interacts with src-family non-receptor tyrosine kinases. , 1998, Journal of cell science.
[106] F. Nikolajeff,et al. The lipid peroxidation metabolite 4-oxo-2-nonenal cross-links alpha-synuclein causing rapid formation of stable oligomers. , 2009, Biochemical and biophysical research communications.
[107] Seho Kim,et al. Characterization of conformational and dynamic properties of natively unfolded human and mouse alpha-synuclein ensembles by NMR: implication for aggregation. , 2008, Journal of molecular biology.
[108] M. Dallas,et al. α‐Synuclein modulation of Ca2+ signaling in human neuroblastoma (SH‐SY5Y) cells , 2009, Journal of neurochemistry.
[109] P. S. St George-Hyslop,et al. alpha-Synuclein membrane interactions and lipid specificity. , 2000, The Journal of biological chemistry.
[110] R. Crowther,et al. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .
[111] Jochen Klucken,et al. Hsp70 Reduces α-Synuclein Aggregation and Toxicity* , 2004, Journal of Biological Chemistry.
[112] Gideon Schreiber,et al. Common crowding agents have only a small effect on protein-protein interactions. , 2009, Biophysical journal.
[113] C. C. Johnson,et al. Parkinson's disease mortality and the industrial use of heavy metals in Michigan , 1993, Movement disorders : official journal of the Movement Disorder Society.
[114] C. Tanner,et al. Environmental factors and Parkinson's disease , 1989, Neurology.
[115] Janel O. Johnson,et al. α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.
[116] J. Rochet,et al. α-Synuclein-induced tubule formation in lipid bilayers. , 2011, The journal of physical chemistry. B.
[117] John Q. Trojanowski,et al. Induction of α-Synuclein Aggregation by Intracellular Nitrative Insult , 2001, The Journal of Neuroscience.
[118] T. Chase,et al. Tissue transglutaminase catalyzes the formation of alpha‐synuclein crosslinks in Parkinson's disease , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[119] C D Marsden,et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. , 1991, Brain : a journal of neurology.
[120] V. Subramaniam,et al. NMR of α‐synuclein–polyamine complexes elucidates the mechanism and kinetics of induced aggregation , 2004, The EMBO journal.
[121] Jian-Dong Huang,et al. Baicalein Inhibits Formation of α‐Synuclein Oligomers within Living Cells and Prevents Aβ Peptide Fibrillation and Oligomerisation , 2011, Chembiochem : a European journal of chemical biology.
[122] S. Lindquist,et al. α-Synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity , 2009, Nature Genetics.
[123] Gang Xiao,et al. Membrane-mediated Amyloidogenesis and the Promotion of Oxidative Lipid Damage by Amyloid β Proteins* , 2007, Journal of Biological Chemistry.
[124] N. Voelcker,et al. Annular alpha-synuclein species from purified multiple system atrophy inclusions. , 2004, Journal of neurochemistry.
[125] L. Golbe. The genetics of Parkinson's disease: A reconsideration , 1990, Neurology.
[126] V. Subramaniam,et al. Tissue transglutaminase modulates α‐synuclein oligomerization , 2008, Protein science : a publication of the Protein Society.
[127] L. Petrucelli,et al. α-Synuclein Shares Physical and Functional Homology with 14-3-3 Proteins , 1999, The Journal of Neuroscience.
[128] R. Nussbaum,et al. Lipid Droplet Binding and Oligomerization Properties of the Parkinson's Disease Protein α-Synuclein* , 2002, The Journal of Biological Chemistry.
[129] M. Raftery,et al. αB-Crystallin is a major component of glial cytoplasmic inclusions in multiple system atrophy , 2009, Neurotoxicity Research.
[130] D. Housman,et al. New Directions for Neurodegenerative Disease Therapy: Using Chemical Compounds to Boost the Formation of Mutant Protein Inclusions , 2006, Cell cycle.
[131] B. Giasson,et al. Effects of Oxidative and Nitrative Challenges on α-Synuclein Fibrillogenesis Involve Distinct Mechanisms of Protein Modifications* , 2003, Journal of Biological Chemistry.
[132] A. Steven,et al. Membrane Curvature Induction and Tubulation Are Common Features of Synucleins and Apolipoproteins* , 2010, The Journal of Biological Chemistry.
[133] A. Singleton,et al. alpha-Synuclein locus triplication causes Parkinson's disease. , 2003, Science.
[134] C. Soto. Prion hypothesis: the end of the controversy? , 2011, Trends in biochemical sciences.
[135] J. Trojanowski,et al. Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies. , 2003, The American journal of pathology.
[136] John S Lazo,et al. Improved low molecular weight Myc-Max inhibitors , 2007, Molecular Cancer Therapeutics.
[137] V. Uversky,et al. Structural characteristics of alpha-synuclein oligomers stabilized by the flavonoid baicalein. , 2008, Journal of molecular biology.
[138] B. Devreese,et al. Transglutaminase-mediated Intramolecular Cross-linking of Membrane-bound α-Synuclein Promotes Amyloid Formation in Lewy Bodies* , 2009, The Journal of Biological Chemistry.
[139] C. Ross,et al. Single Particle Characterization of Iron-induced Pore-forming α-Synuclein Oligomers* , 2008, Journal of Biological Chemistry.
[140] A. Ševčovičová,et al. Phosphorylation , 2013, Cell cycle.
[141] V. Uversky,et al. Agrin binds α-synuclein and modulates α-synuclein fibrillation , 2005 .
[142] M. Kataoka,et al. Chain-like conformation of heat-denatured ribonuclease A and cytochrome c as evidenced by solution X-ray scattering. , 1998, Folding & design.
[143] Daniel Sage,et al. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. , 2008, Human molecular genetics.
[144] A. Roses,et al. The human NACP/alpha-synuclein gene: chromosome assignment to 4q21.3-q22 and TaqI RFLP analysis. , 1995, Genomics.
[145] R. Swerdlow,et al. Microtubule Depolymerization Potentiates Alpha-Synuclein Oligomerization , 2009, Front. Ag. Neurosci..
[146] P. Lansbury,et al. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. , 2003, Biochemistry.
[147] C. Griesinger,et al. Site-specific interactions of Cu(II) with alpha and beta-synuclein: bridging the molecular gap between metal binding and aggregation. , 2008, Journal of the American Chemical Society.
[148] Daniel Otzen,et al. p25α Stimulates α-Synuclein Aggregation and Is Co-localized with Aggregated α-Synuclein in α-Synucleinopathies* , 2005, Journal of Biological Chemistry.
[149] P. Lansbury,et al. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. , 1996, Biochemistry.
[150] John Q. Trojanowski,et al. Ubiquitination of α-Synuclein Is Not Required for Formation of Pathological Inclusions in α-Synucleinopathies , 2003 .
[151] K. Chung,et al. Multiple ligand interaction of α-synuclein produced various forms of protein aggregates in the presence of Aβ25-35, copper, and eosin , 2001, Brain Research.
[152] G. Campanella,et al. [Parkinson disease and environmental factors]. , 1990, Revue d'épidémiologie et de santé publique.
[153] Ji An Wu,et al. Anti-HIV activity of medicinal herbs: usage and potential development. , 2001, The American journal of Chinese medicine.
[154] Ariele Viacava Follis,et al. Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. , 2009, Journal of the American Chemical Society.
[155] Soo-Youl Kim,et al. Tissue transglutaminase-induced aggregation of α-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[156] Vladimir N Uversky,et al. Oncogenic Partnerships: EWS-FLI1 Protein Interactions Initiate Key Pathways of Ewing's Sarcoma , 2010, Clinical Cancer Research.
[157] Patrick R Hof,et al. Distribution and immunohistochemical characterization of torsinA immunoreactivity in rat brain , 2001, Brain Research.
[158] A. Üren,et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing’s sarcoma , 2009 .
[159] Todd B. Sherer,et al. Subcutaneous Rotenone Exposure Causes Highly Selective Dopaminergic Degeneration and α-Synuclein Aggregation , 2003, Experimental Neurology.
[160] E. Masliah,et al. α-Synuclein is phosphorylated in synucleinopathy lesions , 2002, Nature Cell Biology.
[161] R. Bucala,et al. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. , 1992, Advances in pharmacology.
[162] A. Manning-Boğ,et al. Environmental factors in Parkinson's disease. , 2002, Neurotoxicology.
[163] C. Tanner,et al. Rotenone, Paraquat, and Parkinson’s Disease , 2011, Environmental health perspectives.
[164] P J McLean,et al. Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations. , 2000, The Journal of biological chemistry.
[165] F. Kamp,et al. Binding of α-Synuclein Affects the Lipid Packing in Bilayers of Small Vesicles* , 2006, Journal of Biological Chemistry.
[166] Rotenone , 1932, Science.
[167] J. Trojanowski,et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.
[168] Adam J. Trexler,et al. Allostery in a disordered protein: oxidative modifications to α-synuclein act distally to regulate membrane binding. , 2011, Journal of the American Chemical Society.
[169] S. Paik,et al. Structural changes in α‐synuclein affect its chaperone‐like activity in vitro , 2000, Protein science : a publication of the Protein Society.
[170] L. Forsgren,et al. Dietary intake and olfactory function in patients with newly diagnosed Parkinson's disease: a case-control study , 2011, Nutritional neuroscience.
[171] T. Iwatsubo,et al. P4-261 Small molecule inhibitors of alpha-synuclein filament assembly , 2006, Alzheimer's & Dementia.
[172] V. Subramaniam,et al. Dependence of α-synuclein aggregate morphology on solution conditions , 2002 .
[173] Xiaohui Xu,et al. Nitrated α-Synuclein Induces the Loss of Dopaminergic Neurons in the Substantia Nigra of Rats , 2010, PloS one.
[174] Hong-Yu Hu,et al. Interaction with synphilin‐1 promotes inclusion formation of α‐synuclein: mechanistic insights and pathological implication , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[175] M. Bleecker. Parkinsonism: a clinical marker of exposure to neurotoxins. , 1988, Neurotoxicology and teratology.
[176] J. Trojanowski,et al. Parkinson's Disease and Related α‐Synucleinopathies Are Brain Amyloidoses , 2003, Annals of the New York Academy of Sciences.
[177] J. Trojanowski,et al. Induction of alpha-synuclein aggregation by intracellular nitrative insult. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[178] S. Becker,et al. Molecular-level secondary structure, polymorphism, and dynamics of full-length alpha-synuclein fibrils studied by solid-state NMR. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[179] B. Giasson,et al. Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. , 2000, The Journal of biological chemistry.
[180] P. Riederer,et al. Crosslinking of α-synuclein by advanced glycation endproducts — an early pathophysiological step in Lewy body formation? , 2000, Journal of Chemical Neuroanatomy.
[181] W. Bender,et al. A Drosophila model of Parkinson's disease , 2000, Nature.
[182] Tetsuya Takahashi,et al. Activation of Pyk2/RAFTK induces tyrosine phosphorylation of α‐synuclein via Src‐family kinases , 2002 .
[183] Feng Gai,et al. Effect of dehydration on the aggregation kinetics of two amyloid peptides. , 2009, The journal of physical chemistry. B.
[184] Philip J. Thomas,et al. A Precipitating Role for Truncated α-Synuclein and the Proteasome in α-Synuclein Aggregation , 2005, Journal of Biological Chemistry.
[185] Jeff Kuret,et al. Rapid Anionic Micelle-mediated α-Synuclein Fibrillization in Vitro* , 2003, Journal of Biological Chemistry.
[186] Vladimir N Uversky,et al. A Protein-Chameleon: Conformational Plasticity of α-Synuclein, a Disordered Protein Involved in Neurodegenerative Disorders , 2003, Journal of biomolecular structure & dynamics.
[187] J. R. Menezes,et al. Synphilin-1 Is Developmentally Localized to Synaptic Terminals, and Its Association with Synaptic Vesicles Is Modulated by α-Synuclein* , 2002, The Journal of Biological Chemistry.
[188] Jennifer C. Lee,et al. Evidence for copper-dioxygen reactivity during alpha-synuclein fibril formation. , 2010, Journal of the American Chemical Society.
[189] T. Hastings,et al. Alpha‐synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells , 2006, Journal of neurochemistry.
[190] P. Auluck,et al. Pharmacological prevention of Parkinson disease in Drosophila , 2002, Nature Medicine.
[191] David Eisenberg,et al. An amyloid-forming segment of beta2-microglobulin suggests a molecular model for the fibril. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[192] R. Lucchini,et al. From Manganism to Manganese-Induced Parkinsonism: A Conceptual Model Based on the Evolution of Exposure , 2009, NeuroMolecular Medicine.
[193] H. Vorum,et al. Ca2+ Binding to α-Synuclein Regulates Ligand Binding and Oligomerization* , 2001, The Journal of Biological Chemistry.
[194] Olaf Riess,et al. AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.
[195] Bharathi,et al. Copper- and iron-induced differential fibril formation in alpha-synuclein: TEM study. , 2007, Neuroscience letters.
[196] J. Trojanowski,et al. Exogenous α-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells , 2009, Proceedings of the National Academy of Sciences.
[197] Henning Stahlberg,et al. The fold of α-synuclein fibrils , 2008, Proceedings of the National Academy of Sciences.
[198] Bernardino Ghetti,et al. Pathological Changes in Dopaminergic Nerve Cells of the Substantia Nigra and Olfactory Bulb in Mice Transgenic for Truncated Human α-Synuclein(1–120): Implications for Lewy Body Disorders , 2006, The Journal of Neuroscience.
[199] C. Ross,et al. Parkin ubiquitinates the α-synuclein–interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease , 2001, Nature Medicine.
[200] P. Fraser,et al. Small Ubiquitin-like Modifier (SUMO) Modification of Natively Unfolded Proteins Tau and α-Synuclein* , 2006, Journal of Biological Chemistry.
[201] Jennifer Stine Elam,et al. Amyloid-like filaments and water-filled nanotubes formed by SOD1 mutant proteins linked to familial ALS , 2003, Nature Structural Biology.
[202] P. Lansbury,et al. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. , 2000, Biochemistry.
[203] David R. Brown. Metal binding to alpha-synuclein peptides and its contribution to toxicity. , 2009, Biochemical and biophysical research communications.
[204] A. Fink. The aggregation and fibrillation of alpha-synuclein. , 2006, Accounts of chemical research.
[205] Armin Giese,et al. Different Species of α-Synuclein Oligomers Induce Calcium Influx and Seeding , 2007, The Journal of Neuroscience.
[206] T. Ly,et al. Protein-metal interactions of calmodulin and α-synuclein monitored by selective noncovalent adduct protein probing mass spectrometry , 2008, Journal of the American Society for Mass Spectrometry.
[207] N. Voelcker,et al. Annular α‐synuclein species from purified multiple system atrophy inclusions , 2004 .
[208] William C. Nolan,et al. Curcumin inhibits aggregation of α-synuclein , 2008, Acta Neuropathologica.
[209] G. Petsko,et al. The oxidation state of DJ-1 regulates its chaperone activity toward alpha-synuclein. , 2006, Journal of molecular biology.
[210] J. Payton,et al. Protein-protein interactions of alpha-synuclein in brain homogenates and transfected cells. , 2001, Brain research. Molecular brain research.
[211] R. Kayed,et al. Permeabilization of Lipid Bilayers Is a Common Conformation-dependent Activity of Soluble Amyloid Oligomers in Protein Misfolding Diseases* , 2004, Journal of Biological Chemistry.
[212] M. Ekberg,et al. The lipid peroxidation products 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote the formation of α-synuclein oligomers with distinct biochemical, morphological, and functional properties. , 2011, Free radical biology & medicine.
[213] Martin Blackledge,et al. Amino acid bulkiness defines the local conformations and dynamics of natively unfolded alpha-synuclein and tau. , 2007, Journal of the American Chemical Society.
[214] Y. Amemiya,et al. Protein globularization during folding. A study by synchrotron small-angle X-ray scattering. , 1996, Journal of Molecular Biology.
[215] P. Højrup,et al. α-Synuclein Binds to Tau and Stimulates the Protein Kinase A-catalyzed Tau Phosphorylation of Serine Residues 262 and 356* , 1999, The Journal of Biological Chemistry.
[216] Kiowa S. Bower,et al. Accelerated α‐synuclein fibrillation in crowded milieu , 2002 .
[217] C. Masters,et al. Cu2+ binding modes of recombinant alpha-synuclein--insights from EPR spectroscopy. , 2008, Journal of the American Chemical Society.
[218] C. Griesinger,et al. Structural characterization of copper(II) binding to alpha-synuclein: Insights into the bioinorganic chemistry of Parkinson's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[219] Jie Li,et al. The Association of α-Synuclein with Membranes Affects Bilayer Structure, Stability, and Fibril Formation* , 2003, Journal of Biological Chemistry.
[220] Harry B Gray,et al. Alpha-synuclein tertiary contact dynamics. , 2007, The journal of physical chemistry. B.
[221] K. Takata,et al. Parkinsonian rotenone mouse model: reevaluation of long-term administration of rotenone in C57BL/6 mice. , 2011, Biological & pharmaceutical bulletin.
[222] V. Subramaniam,et al. Dependence of alpha-synuclein aggregate morphology on solution conditions. , 2002, Journal of molecular biology.
[223] Paul H. Axelsen,et al. The E46K Mutation in α-Synuclein Increases Amyloid Fibril Formation* , 2005, Journal of Biological Chemistry.
[224] R. Ellis. Macromolecular crowding : obvious but underappreciated , 2022 .
[225] P. S. St George-Hyslop,et al. α-Synuclein Membrane Interactions and Lipid Specificity* , 2000, The Journal of Biological Chemistry.
[226] L. Breydo,et al. Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. , 2007, Biochemistry.
[227] W. Dauer,et al. Parkinson's Disease Mechanisms and Models , 2003, Neuron.
[228] I. Ziv,et al. Mutant and wild-type alpha-synuclein interact with mitochondrial cytochrome C oxidase. , 2002, Journal of molecular neuroscience : MN.
[229] S. Metallo,et al. Intrinsically disordered proteins are potential drug targets. , 2010, Current opinion in chemical biology.
[230] A. Levey,et al. Functional Interaction between Monoamine Plasma Membrane Transporters and the Synaptic PDZ Domain–Containing Protein PICK1 , 2001, Neuron.
[231] Brian Spencer,et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein , 2009, Proceedings of the National Academy of Sciences.
[232] V. Uversky,et al. Pesticides directly accelerate the rate of α‐synuclein fibril formation: a possible factor in Parkinson's disease , 2001, FEBS letters.
[233] Vladimir N Uversky,et al. Conformational behavior of human alpha-synuclein is modulated by familial Parkinson's disease point mutations A30P and A53T. , 2002, Neurotoxicology.
[234] M. Davies,et al. The oxidative environment and protein damage. , 2005, Biochimica et biophysica acta.
[235] H. Kato,et al. Calcium-triggered membrane interaction of the alpha-synuclein acidic tail. , 2006, Biochemistry.
[236] G J Pielak,et al. Solvent-induced collapse of alpha-synuclein and acid-denatured cytochrome c. , 2001, Protein science : a publication of the Protein Society.
[237] D. Eliezer,et al. Residual structure, backbone dynamics, and interactions within the synuclein family. , 2007, Journal of molecular biology.
[238] J. Hicks,et al. The Transition Metals , 1971 .
[239] Heather T. McFarlane,et al. Atomic structures of amyloid cross-β spines reveal varied steric zippers , 2007, Nature.
[240] M Yasui,et al. Calcium, magnesium and aluminum concentrations in Parkinson's disease. , 1992, Neurotoxicology.
[241] O. Hornykiewicz,et al. α-Synuclein selectively increases manganese-induced viability loss in SK-N-MC neuroblastoma cells expressing the human dopamine transporter , 2004, Neuroscience Letters.
[242] M. Frasier,et al. Magnesium Inhibits Spontaneous and Iron-induced Aggregation of α-Synuclein* , 2002, The Journal of Biological Chemistry.
[243] B. Hyman,et al. Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. , 2004, The Journal of biological chemistry.
[244] R. Scheller,et al. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[245] B. Hyman,et al. Interaction of α‐synuclein and synphilin‐1: effect of Parkinson's disease‐associated mutations , 2001 .
[246] E. Altschuler,et al. Aluminum-containing antacids as a cause of idiopathic Parkinson's disease. , 1999, Medical hypotheses.
[247] A. Zoleo,et al. Structural characterization of a high affinity mononuclear site in the copper(II)-α-synuclein complex. , 2010, Journal of the American Chemical Society.
[248] P. Fraser,et al. α‐Synuclein–synaptosomal membrane interactions , 2004 .
[249] D. Bushinsky,et al. Calcium , 1998, The Lancet.
[250] M. Citron,et al. Both Familial Parkinson’s Disease Mutations Accelerate α-Synuclein Aggregation* , 1999, The Journal of Biological Chemistry.
[251] A. Goldberg,et al. PAN, the proteasome-activating nucleotidase from archaebacteria, is a protein-unfolding molecular chaperone , 2000, Nature Cell Biology.
[252] Sun-Young Lee,et al. α‐Synuclein exhibits competitive interaction between calmodulin and synthetic membranes , 2002, Journal of neurochemistry.
[253] L. Serpell,et al. Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. , 2004, FEBS letters.
[254] V. Uversky,et al. Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils. , 2004, Chemistry & biology.
[255] P. Worley,et al. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. , 1999, Nature genetics.
[256] Jeff Kuret,et al. Rapid anionic micelle-mediated alpha-synuclein fibrillization in vitro. , 2003, The Journal of biological chemistry.
[257] R. Perrin,et al. Interaction of human alpha-Synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. , 2000, The Journal of biological chemistry.
[258] V. Uversky,et al. The Herbicide Paraquat Causes Up-regulation and Aggregation of α-Synuclein in Mice , 2002, The Journal of Biological Chemistry.
[259] V. Subramaniam,et al. Membrane interactions of oligomeric alpha-synuclein: potential role in Parkinson's disease. , 2010, Current protein & peptide science.
[260] H. Lashuel,et al. Stable α-Synuclein Oligomers Strongly Inhibit Chaperone Activity of the Hsp70 System by Weak Interactions with J-domain Co-chaperones* , 2010, The Journal of Biological Chemistry.
[261] Gabriele Meloni,et al. Redox activity of α-synuclein-Cu is silenced by Zn₇-metallothionein-3. , 2011, Free radical biology & medicine.
[262] David Eisenberg,et al. Recent atomic models of amyloid fibril structure. , 2006, Current opinion in structural biology.
[263] Sebastian Doniach,et al. Biophysical Properties of the Synucleins and Their Propensities to Fibrillate , 2002, The Journal of Biological Chemistry.
[264] F. Kamp,et al. Binding of alpha-synuclein affects the lipid packing in bilayers of small vesicles. , 2006, The Journal of biological chemistry.
[265] R. Perrin,et al. Exposure to Long Chain Polyunsaturated Fatty Acids Triggers Rapid Multimerization of Synucleins* , 2001, The Journal of Biological Chemistry.
[266] J. Langston,et al. Environmental Risk Factors and Parkinson's Disease: Selective Degeneration of Nigral Dopaminergic Neurons Caused by the Herbicide Paraquat , 2002, Neurobiology of Disease.
[267] C. Griesinger,et al. Exploring the structural details of Cu(I) binding to α-synuclein by NMR spectroscopy. , 2011, Journal of the American Chemical Society.
[268] Robert L. Nussbaum,et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .
[269] P Choi,et al. alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. , 1999, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[270] C. Dobson,et al. Structure and properties of a complex of α-synuclein and a single-domain camelid antibody. , 2010, Journal of molecular biology.
[271] G. G. Stokes. "J." , 1890, The New Yale Book of Quotations.
[272] L. Meijer,et al. Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. , 2000, The Journal of biological chemistry.
[273] Daniel Harries,et al. Crowding Alone Cannot Account for Cosolute Effect on Amyloid Aggregation , 2011, PloS one.
[274] S Doniach,et al. Changes in biomolecular conformation seen by small angle X-ray scattering. , 2001, Chemical reviews.
[275] V. Uversky,et al. Agrin binds alpha-synuclein and modulates alpha-synuclein fibrillation. , 2005, Glycobiology.
[276] Guifang Wang,et al. 19F NMR studies of alpha-synuclein conformation and fibrillation. , 2009, Biochemistry.
[277] J. Trojanowski,et al. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. , 2002, Neuron.
[278] A. Fink. The Aggregation and Fibrillation of α-Synuclein , 2006 .
[279] Pico Caroni,et al. Neuropathology in Mice Expressing Human α-Synuclein , 2000, The Journal of Neuroscience.
[280] Patrick S Daugherty,et al. Evolutionary optimization of fluorescent proteins for intracellular FRET , 2005, Nature Biotechnology.
[281] Chi V. Dang,et al. c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism , 1999, Molecular and Cellular Biology.
[282] B. Hyman,et al. Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation. , 2006, Biochemical and biophysical research communications.
[283] T. Iwatsubo,et al. Ubiquitination of alpha-synuclein. , 2005, Biochemistry.
[284] J. Kelly,et al. The oxidative stress metabolite 4-hydroxynonenal promotes Alzheimer protofibril formation. , 2007, Biochemistry.
[285] D. Ehrnhoefer,et al. EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity , 2010, Proceedings of the National Academy of Sciences.
[286] Fred H. Gage,et al. In vivo demonstration that α-synuclein oligomers are toxic , 2011, Proceedings of the National Academy of Sciences.
[287] Birgit Schilling,et al. Preferentially increased nitration of alpha-synuclein at tyrosine-39 in a cellular oxidative model of Parkinson's disease. , 2009, Analytical chemistry.
[288] V. Uversky,et al. Certain Metals Trigger Fibrillation of Methionine-oxidized α-Synuclein* , 2003, Journal of Biological Chemistry.
[289] T. Iwatsubo,et al. Ubiquitination of α-Synuclein† , 2005 .
[290] Ralf Langen,et al. A combinatorial NMR and EPR approach for evaluating the structural ensemble of partially folded proteins. , 2010, Journal of the American Chemical Society.
[291] E. Israeli,et al. β‐Synuclein occurs in vivo in lipid‐associated oligomers and forms hetero‐oligomers with α‐synuclein , 2009, Journal of neurochemistry.
[292] A. Young,et al. Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[293] Paul R. Carey,et al. Secondary Structure of α-Synuclein Oligomers: Characterization by Raman and Atomic Force Microscopy , 2006 .
[294] E. Masliah,et al. beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. , 2001, Neuron.
[295] V. Uversky. Intrinsically Disordered Proteins , 2014 .
[296] M. Zigmond,et al. Erratum: "A role for α-synuclein in the regulation of dopamine biosynthesis" The Journal of Neuroscience (April 15, 2002) (3090-3099)) , 2002 .
[297] V. Uversky,et al. Smoking and Parkinson's disease: does nicotine affect alpha-synuclein fibrillation? , 2009, Biochimica et biophysica acta.
[298] Mark A. Wilson,et al. The oxidation state of DJ-1 regulates its chaperone activity toward α-synuclein , 2006 .
[299] A. Matouschek,et al. Aggregated and Monomeric α-Synuclein Bind to the S6′ Proteasomal Protein and Inhibit Proteasomal Function* , 2003, The Journal of Biological Chemistry.
[300] Ji-Eun Suk,et al. Dopamine promotes formation and secretion of non-fibrillar alpha-synuclein oligomers , 2011, Experimental & Molecular Medicine.
[301] Jennifer C. Lee,et al. Identification of the minimal copper(II)-binding alpha-synuclein sequence. , 2009, Inorganic chemistry.
[302] Zhengguo Zhou,et al. Crowded Cell-like Environment Accelerates the Nucleation Step of Amyloidogenic Protein Misfolding* , 2009, The Journal of Biological Chemistry.
[303] I. Kanazawa,et al. α-Synuclein Affects the MAPK Pathway and Accelerates Cell Death* , 2001, The Journal of Biological Chemistry.
[304] L. Stefanis,et al. α-Synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells , 2005, Journal of Cell Science.
[305] V. Uversky,et al. Nitration inhibits fibrillation of human α‐synuclein in vitro by formation of soluble oligomers , 2003 .
[306] M. Yoshimoto,et al. NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[307] P. Højrup,et al. &agr;-Synuclein filaments bind the transcriptional regulator HMGB-1 , 2004, Neuroreport.
[308] Donato A Di Monte,et al. The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? , 2003, The Lancet Neurology.
[309] S E Ide,et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.
[310] H. Ischiropoulos,et al. Biological selectivity and functional aspects of protein tyrosine nitration. , 2003, Biochemical and biophysical research communications.
[311] M. Sierks,et al. Curcumin reduces α-synuclein induced cytotoxicity in Parkinson's disease cell model , 2010, BMC Neuroscience.
[312] J. Trojanowski,et al. Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. , 2003, Biochemistry.
[313] J. Rochet,et al. Adsorption of alpha-synuclein on lipid bilayers: modulating the structure and stability of protein assemblies. , 2010, The journal of physical chemistry. B.
[314] R. Kayed,et al. Small Molecule Inhibitors of Aggregation Indicate That Amyloid β Oligomerization and Fibrillization Pathways Are Independent and Distinct* , 2007, Journal of Biological Chemistry.
[315] S. Shaikh,et al. Advanced glycation end products induce in vitro cross‐linking of α‐synuclein and accelerate the process of intracellular inclusion body formation , 2008, Journal of neuroscience research.
[316] S. Zimmerman,et al. Estimation of macromolecule concentrations and excluded volume effects for the cytoplasm of Escherichia coli. , 1991, Journal of molecular biology.
[317] D. Sulzer,et al. Interplay between Cytosolic Dopamine, Calcium, and α-Synuclein Causes Selective Death of Substantia Nigra Neurons , 2009, Neuron.
[318] R. Hauser,et al. Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease , 2008, Nature Medicine.
[319] B. Hyman,et al. Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. , 2009, The Journal of clinical investigation.
[320] Todd B. Sherer,et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.
[321] V. Uversky,et al. Role of protein-water interactions and electrostatics in alpha-synuclein fibril formation. , 2004, Biochemistry.
[322] K. Rao,et al. Role of advanced glycation on aggregation and DNA binding properties of α-synuclein. , 2011, Journal of Alzheimer's disease : JAD.
[323] A. Singleton,et al. Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication. , 2004, Brain : a journal of neurology.
[324] N. Maiti,et al. Secondary structure of alpha-synuclein oligomers: characterization by raman and atomic force microscopy. , 2006, Journal of molecular biology.
[325] A. Fink,et al. Conformational states of beta-lactamase: molten-globule states at acidic and alkaline pH with high salt. , 1989, Biochemistry.
[326] Jing Zhang,et al. Identification of Novel Proteins Associated with Both α-Synuclein and DJ-1*S , 2007, Molecular & Cellular Proteomics.
[327] G. Anantharamaiah,et al. The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. , 1992, Journal of lipid research.
[328] K. Arima,et al. Tubulin Seeds α-Synuclein Fibril Formation* , 2002, The Journal of Biological Chemistry.
[329] D. Allsop,et al. Formation of hydrogen peroxide and hydroxyl radicals from Aβ and α-synuclein as a possible mechanism of cell death in Alzheimer’s disease and Parkinson’s disease. , 2002 .
[330] J. Gorell,et al. Occupational Metal Exposures and the Risk of Parkinson’s Disease , 1999, Neuroepidemiology.
[331] B. Wolozin,et al. Book Review: Iron and Parkinson’s Disease , 2002, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.
[332] A. Doig,et al. A study of the regional effects of alpha-synuclein on the organization and stability of phospholipid bilayers. , 2006, Biochemistry.
[333] P. Jensen,et al. Pathogenic effects of α-synuclein aggregation , 2005 .
[334] C. Olanow,et al. Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study , 1994, Brain Research.
[335] P. Lansbury,et al. Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease? , 2002, Biochemistry.
[336] D. Raleigh,et al. A role for helical intermediates in amyloid formation by natively unfolded polypeptides? , 2009, Physical biology.
[337] C. Tanner,et al. The role of environmental toxins in the etiology of Parkinson's disease , 1989, Trends in Neurosciences.
[338] Dmitri I Svergun,et al. Low-resolution structure of a vesicle disrupting α-synuclein oligomer that accumulates during fibrillation , 2011, Proceedings of the National Academy of Sciences.
[339] Vladimir N Uversky,et al. Intrinsically disordered proteins from A to Z. , 2011, The international journal of biochemistry & cell biology.
[340] V. Uversky,et al. Metalloproteomics and metal toxicology of α-synuclein. , 2010, Metallomics : integrated biometal science.
[341] J. Winderickx,et al. Yeast unfolds the road map toward α-synuclein-induced cell death , 2010, Cell Death and Differentiation.
[342] A. Barbeau,et al. Manganese and extrapyramidal disorders (a critical review and tribute to Dr. George C. Cotzias). , 1984, Neurotoxicology.
[343] Shubo Han,et al. The Flavonoid Baicalein Inhibits Fibrillation of α-Synuclein and Disaggregates Existing Fibrils* , 2004, Journal of Biological Chemistry.
[344] D. Eliezer,et al. Residual Structure and Dynamics in Parkinson's Disease-associated Mutants of α-Synuclein* , 2001, The Journal of Biological Chemistry.
[345] Olga Pletnikova,et al. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[346] J. Toretsky,et al. Recombinant EWS-FLI1 oncoprotein activates transcription. , 2004, Biochemistry.
[347] Kiowa S. Bower,et al. Synergistic effects of pesticides and metals on the fibrillation of alpha-synuclein: implications for Parkinson's disease. , 2002, Neurotoxicology.
[348] Armin Giese,et al. Different species of alpha-synuclein oligomers induce calcium influx and seeding. , 2007, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[349] Y. Agid,et al. Iron and Aluminum Increase in the Substantia Nigra of Patients with Parkinson's Disease: An X‐Ray Microanalysis , 1991, Journal of neurochemistry.
[350] S. Lindquist,et al. α-Synuclein: membrane interactions and toxicity in Parkinson's disease. , 2010, Annual review of cell and developmental biology.
[351] J Kim,et al. Aluminum-induced structural alterations of the precursor of the non-A beta component of Alzheimer's disease amyloid. , 1997, Archives of biochemistry and biophysics.
[352] R. Uitti,et al. Regional Metal Concentrations in Parkinson's Disease, Other Chronic Neurological Diseases, and Control Brains , 1989, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[353] K. Chung,et al. The role of ubiquitin linkages on α‐synuclein induced‐toxicity in a Drosophila model of Parkinson’s disease , 2009, Journal of neurochemistry.
[354] Natively unfolded human prothymosin alpha adopts partially folded collapsed conformation at acidic pH. , 1999 .
[355] J. Mallet,et al. Rat alpha-synuclein interacts with Tat binding protein 1, a component of the 26S proteasomal complex. , 2000, Journal of neurochemistry.
[356] K. Jellinger,et al. The role of transition metals in the pathogenesis of Parkinson's disease , 1995, Journal of the Neurological Sciences.
[357] E. Masliah,et al. Phosphorylation at S87 Is Enhanced in Synucleinopathies, Inhibits α-Synuclein Oligomerization, and Influences Synuclein-Membrane Interactions , 2010, The Journal of Neuroscience.
[358] V. Uversky. Alpha-synuclein misfolding and neurodegenerative diseases. , 2008, Current protein & peptide science.
[359] E. Walter,et al. Coordination features and affinity of the Cu²+ site in the α-synuclein protein of Parkinson's disease. , 2011, Biochemistry.
[360] John Q. Trojanowski,et al. Chaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease , 2001, Science.
[361] P. Axelsen,et al. Role of α-Synuclein Carboxy-Terminus on Fibril Formation in Vitro† , 2003 .
[362] A. Fink,et al. Classification of acid denaturation of proteins: intermediates and unfolded states. , 1994, Biochemistry.
[363] V. Uversky,et al. Methionine oxidation, alpha-synuclein and Parkinson's disease. , 2005, Biochimica et biophysica acta.
[364] David R. Brown,et al. Opus: University of Bath Online Publication Store Alpha-synuclein Is a Cellular Ferrireductase , 2022 .
[365] D. Eliezer,et al. NMR mapping of copper binding sites in alpha-synuclein. , 2006, Biochimica et biophysica acta.
[366] R. Kayed,et al. Annular Protofibrils Are a Structurally and Functionally Distinct Type of Amyloid Oligomer* , 2009, Journal of Biological Chemistry.
[367] Toshiki Nakai,et al. Prolyl-isomerase Pin1 Accumulates in Lewy Bodies of Parkinson Disease and Facilitates Formation of α-Synuclein Inclusions* , 2006, Journal of Biological Chemistry.
[368] H. Lashuel,et al. Towards elucidation of the role of ubiquitination in the pathogenesis of Parkinson's disease with semisynthetic ubiquitinated α-synuclein. , 2011, Angewandte Chemie.
[369] L. Bubacco,et al. Dopamine quinones interact with alpha-synuclein to form unstructured adducts. , 2010, Biochemical and biophysical research communications.
[370] D. Marsh,et al. Association of α-synuclein and mutants with lipid membranes: spin-label ESR and polarized IR. , 2006 .
[371] E. Masliah,et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. , 2002, Nature cell biology.
[372] R. Krüger,et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.
[373] E. Masliah,et al. Protein aggregate spreading in neurodegenerative diseases: Problems and perspectives , 2011, Neuroscience Research.
[374] M. Brin,et al. Immunohistochemical localization and distribution of torsinA in normal human and rat brain , 2000, Brain Research.
[375] Min Zhu,et al. Lipid binding inhibits alpha-synuclein fibril formation. , 2003, The Journal of biological chemistry.
[376] N. Voelcker,et al. Annular alpha-synuclein oligomers are potentially toxic agents in alpha-synucleinopathy. Hypothesis , 2009, Neurotoxicity Research.
[377] Zsuzsanna Dosztányi,et al. IUPred: web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content , 2005, Bioinform..
[378] S. Doglia,et al. Compact conformations of α‐synuclein induced by alcohols and copper , 2011, Proteins.
[379] J. Eibl,et al. The association of metal ion exposure with alpha-synuclein-like immunoreactivity in the central nervous system of fish, Catostomus commersoni. , 2009, Aquatic toxicology.
[380] P. Lansbury,et al. The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states. , 2007, Biochemistry.
[381] J. Trojanowski,et al. Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein , 2002, Neuron.
[382] V. Uversky,et al. Accelerated fibrillation of alpha-synuclein induced by the combined action of macromolecular crowding and factors inducing partial folding. , 2009, Current Alzheimer research.
[383] P. Lansbury,et al. Accelerated Oligomerization by Parkinson's Disease Linked α‐Synuclein Mutants , 2000 .
[384] V. Uversky,et al. Certain metals trigger fibrillation of methionine-oxidized alpha-synuclein. , 2003, The Journal of biological chemistry.
[385] T. Iwatsubo,et al. Accumulation of phosphorylated alpha-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy. , 2004, Acta neuropathologica.
[386] V. Uversky,et al. Nuclear Localization of α-Synuclein and Its Interaction with Histones† , 2003 .
[387] Jimin Wang,et al. A regulatable switch mediates self-association in an immunoglobulin fold , 2008, Nature Structural &Molecular Biology.
[388] E. Morignat,et al. Transmission of Prion Strains in a Transgenic Mouse Model Overexpressing Human A53T Mutated &agr;-Synuclein , 2011, Journal of neuropathology and experimental neurology.
[389] D. D. Di Monte,et al. Effect of 4-Hydroxy-2-nonenal Modification on α-Synuclein Aggregation* , 2007, Journal of Biological Chemistry.
[390] N. Bonini,et al. DJ‐1 is present in a large molecular complex in human brain tissue and interacts with α‐synuclein , 2005, Journal of neurochemistry.
[391] I. Kanazawa,et al. α‐Synuclein forms a complex with transcription factor Elk‐1 , 2001, Journal of neurochemistry.
[392] L. Mucke,et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. , 2000, Science.
[393] P. Lansbury,et al. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[394] H. Dyson,et al. Intrinsically unstructured proteins and their functions , 2005, Nature Reviews Molecular Cell Biology.
[395] P. Højrup,et al. Binding of Abeta to alpha- and beta-synucleins: identification of segments in alpha-synuclein/NAC precursor that bind Abeta and NAC. , 1997, The Biochemical journal.
[396] P. Aebischer,et al. α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[397] V. Uversky,et al. The effect of macromolecular crowding on protein aggregation and amyloid fibril formation , 2004, Journal of molecular recognition : JMR.
[398] C. Fernández,et al. Structures behind the amyloid aggregation of alpha-synuclein: an NMR based approach. , 2011 .
[399] M. Feany,et al. α-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease , 2005, Nature Neuroscience.
[400] Carl W. Cotman,et al. Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.
[401] H De Loof,et al. Amphipathic helix motif: Classes and properties , 1990, Proteins.
[402] C. C. Johnson,et al. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. , 1999, Neurotoxicology.
[403] V. Uversky,et al. Rifampicin Inhibits α-Synuclein Fibrillation and Disaggregates Fibrils , 2004 .
[404] K. Kuwajima,et al. Structural characterization of the molten globule of α‐lactalbumin by solution X‐ray scattering , 1997, Protein science : a publication of the Protein Society.
[405] C. Griesinger,et al. Familial Mutants of α-Synuclein with Increased Neurotoxicity Have a Destabilized Conformation* , 2005, Journal of Biological Chemistry.
[406] S. Chandra,et al. αβγ-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction , 2010, Proceedings of the National Academy of Sciences.
[407] Makoto Hashimoto,et al. β-Synuclein Inhibits α-Synuclein Aggregation A Possible Role as an Anti-Parkinsonian Factor , 2001, Neuron.
[408] Zeger Debyser,et al. The aggregation of alpha‐synuclein is stimulated by FK506 binding proteins as shown by fluorescence correlation spectroscopy , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[409] R. Aebersold,et al. Mass spectrometry in proteomics. , 2001, Chemical reviews.
[410] J. Dordick,et al. Polyphenolic Glycosides and Aglycones Utilize Opposing Pathways To Selectively Remodel and Inactivate Toxic Oligomers of Amyloid β , 2011, Chembiochem : a European journal of chemical biology.
[411] T. Iwatsubo,et al. Accumulation of phosphorylated α-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy , 2004, Acta Neuropathologica.
[412] B. Hyman,et al. Interaction of alpha-synuclein and synphilin-1: effect of Parkinson's disease-associated mutations. , 2001, Journal of neurochemistry.
[413] B. Hyman,et al. Small Heat Shock Proteins Protect Against α-Synuclein-Induced Toxicity and Aggregation , 2006 .
[414] N. Makarava,et al. Molecular Structure of Amyloid Fibrils Controls the Relationship between Fibrillar Size and Toxicity , 2011, PloS one.
[415] C. C. Lin,et al. Antioxidant and free radical scavenging effects of baicalein, baicalin and wogonin. , 2000, Anticancer research.
[416] Matthew P Frosch,et al. The Formation of Highly Soluble Oligomers of α-Synuclein Is Regulated by Fatty Acids and Enhanced in Parkinson's Disease , 2003, Neuron.
[417] Roberto Cappai,et al. Modulation of α-Synuclein Aggregation by Dopamine: A Review , 2009, Neurochemical Research.
[418] P. Fraser,et al. alpha-Synuclein-synaptosomal membrane interactions: implications for fibrillogenesis. , 2004, European journal of biochemistry.
[419] P. Romero,et al. Sequence complexity of disordered protein , 2001, Proteins.
[420] M. Shoji,et al. A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human alpha-synuclein A30P + A53T transgenic mice. , 2009, Parkinsonism & related disorders.
[421] E. Waxman,et al. Induction of Intracellular Tau Aggregation Is Promoted by α-Synuclein Seeds and Provides Novel Insights into the Hyperphosphorylation of Tau , 2011, The Journal of Neuroscience.
[422] Ulrik Gether,et al. Regulation of dopamine transporter function by protein‐protein interactions: new discoveries and methodological challenges , 2010, Journal of neurochemistry.
[423] Martin Blackledge,et al. NMR characterization of long-range order in intrinsically disordered proteins. , 2010, Journal of the American Chemical Society.
[424] J. Hoenicka,et al. The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.
[425] David Eisenberg,et al. Structures of segments of α‐synuclein fused to maltose‐binding protein suggest intermediate states during amyloid formation , 2011, Protein science : a publication of the Protein Society.
[426] A. Bush,et al. Metals and neuroscience. , 2000, Current opinion in chemical biology.
[427] Michel Goedert,et al. Mutation E46K increases phospholipid binding and assembly into filaments of human α‐synuclein , 2004 .
[428] J. Hahn,et al. Granular Assembly of α-Synuclein Leading to the Accelerated Amyloid Fibril Formation with Shear Stress , 2009, PloS one.
[429] M. Stefani,et al. Biochemical and biophysical features of both oligomer/fibril and cell membrane in amyloid cytotoxicity , 2010, The FEBS journal.
[430] Harry B. Gray,et al. α-Synuclein Tertiary Contact Dynamics , 2007 .
[431] V. Uversky,et al. Effects of Various Flavonoids on the α-Synuclein Fibrillation Process , 2010, Parkinson's disease.
[432] P. Lansbury,et al. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. , 2002, Journal of molecular biology.
[433] C. Tanner,et al. Environmental Factors in the Etiology of Parkinson's Disease , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[434] Smita Patel,et al. Golgi Fragmentation Occurs in the Cells with Prefibrillar α-Synuclein Aggregates and Precedes the Formation of Fibrillar Inclusion* , 2002, The Journal of Biological Chemistry.
[435] Christopher G. Adda,et al. Interaction of the Molecular Chaperone αB-Crystallin with α-Synuclein: Effects on Amyloid Fibril Formation and Chaperone Activity , 2004 .
[436] E. Bergantino,et al. Conformational Equilibria in Monomeric α-Synuclein at the Single-Molecule Level , 2008, PLoS biology.
[437] B. Hyman,et al. CHIP Targets Toxic α-Synuclein Oligomers for Degradation* , 2008, Journal of Biological Chemistry.
[438] T. Yeates,et al. Arrangement of subunits and ordering of beta-strands in an amyloid sheet. , 2002, Nature structural biology.
[439] Nobutaka Hattori,et al. Ubiquitination of a New Form of α-Synuclein by Parkin from Human Brain: Implications for Parkinson's Disease , 2001, Science.
[440] J. Trojanowski,et al. Mutant and Wild Type Human α-Synucleins Assemble into Elongated Filaments with Distinct Morphologies in Vitro * , 1999, The Journal of Biological Chemistry.
[441] A. Singleton,et al. Association between cardiac denervation and parkinsonism caused by α‐synuclein gene triplication , 2004 .
[442] M G Spillantini,et al. Alpha-synuclein in Lewy bodies. , 1997, Nature.
[443] J. Trojanowski,et al. Interactions between Hsp70 and the hydrophobic core of alpha-synuclein inhibit fibril assembly. , 2008, Biochemistry.
[444] Isao Nishimura,et al. Parkin Suppresses Dopaminergic Neuron-Selective Neurotoxicity Induced by Pael-R in Drosophila , 2003, Neuron.
[445] V. Uversky,et al. Methionine oxidation, a-synuclein and Parkinson's disease , 2005 .
[446] D. Lynch,et al. Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. , 2004, The Journal of biological chemistry.
[447] Jane R. Allison,et al. Determination of the free energy landscape of alpha-synuclein using spin label nuclear magnetic resonance measurements. , 2009, Journal of the American Chemical Society.
[448] Takeshi Nakamura,et al. Activation of Pyk2/RAFTK induces tyrosine phosphorylation of alpha-synuclein via Src-family kinases. , 2002, FEBS letters.
[449] Vladimir N Uversky,et al. Guiding protein aggregation with macromolecular crowding. , 2008, Biochemistry.
[450] Robert A. Grothe,et al. Structure of the cross-beta spine of amyloid-like fibrils. , 2005, Nature.
[451] Y. Sung,et al. α-Synuclein Interacts with Phospholipase D Isozymes and Inhibits Pervanadate-induced Phospholipase D Activation in Human Embryonic Kidney-293 Cells* , 2002, The Journal of Biological Chemistry.
[452] F. Marken,et al. The synucleins are a family of redox-active copper binding proteins. , 2011, Biochemistry.
[453] N. Hattori,et al. [Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease]. , 2004, Rinsho shinkeigaku = Clinical neurology.
[454] Josephine A. Wright,et al. Unique copper‐induced oligomers mediate alpha‐synuclein toxicity , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[455] T. Ulmer,et al. α-Synuclein Populates Both Elongated and Broken Helix States on Small Unilamellar Vesicles , 2011, The Journal of Biological Chemistry.
[456] Songsong Cao,et al. Hypothesis-based RNAi screening identifies neuroprotective genes in a Parkinson's disease model , 2008, Proceedings of the National Academy of Sciences.
[457] V. Subramaniam,et al. Membrane Permeabilization by Oligomeric α-Synuclein: In Search of the Mechanism , 2010, PloS one.
[458] Mark R Cookson,et al. The biochemistry of Parkinson's disease. , 2005, Annual review of biochemistry.
[459] Jennifer C. Lee,et al. Copper(II) Binding to α-Synuclein, the Parkinson’s Protein , 2008, Journal of the American Chemical Society.
[460] A. Fink,et al. Mechanism of acid-induced folding of proteins. , 1990, Biochemistry.
[461] L. Meijer,et al. Constitutive Phosphorylation of the Parkinson's Disease Associated α-Synuclein* , 2000, The Journal of Biological Chemistry.
[462] C. Griesinger,et al. Familial mutants of alpha-synuclein with increased neurotoxicity have a destabilized conformation. , 2005, Journal of Biological Chemistry.
[463] V. Uversky,et al. Role of Protein−Water Interactions and Electrostatics in α-Synuclein Fibril Formation† , 2004 .
[464] Peter T. Lansbury,et al. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease , 1998, Nature Medicine.
[465] David R. Brown. Oligomeric alpha‐synuclein and its role in neuronal death , 2010, IUBMB life.
[466] A. Ashcroft,et al. Metals accelerate the formation and direct the structure of amyloid fibrils of NAC. , 2005, Journal of inorganic biochemistry.
[467] H. Lashuel,et al. The anti-Parkinsonian drug selegiline delays the nucleation phase of α-synuclein aggregation leading to the formation of nontoxic species. , 2011, Journal of molecular biology.
[468] M. Feany,et al. Aggregated α-Synuclein Mediates Dopaminergic Neurotoxicity In Vivo , 2007, The Journal of Neuroscience.
[469] A. Fulton,et al. How crowded is the cytoplasm? , 1982, Cell.
[470] C. Griesinger,et al. Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[471] H. Esterbauer,et al. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. , 1991, Free radical biology & medicine.
[472] A. Morris,et al. Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. , 1998, Biochemistry.
[473] K. Beyer. α-Synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers , 2006, Acta Neuropathologica.
[474] C. Dobson,et al. Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations. , 2005, Journal of the American Chemical Society.
[475] C. Griesinger,et al. Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement. , 2006, Journal of the American Chemical Society.
[476] K. Arima,et al. Tubulin seeds alpha-synuclein fibril formation. , 2002, The Journal of biological chemistry.
[477] M. Frasier,et al. Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. , 2002, The Journal of biological chemistry.
[478] E. Masliah,et al. Enhanced Phosphatase Activity Attenuates α-Synucleinopathy in a Mouse Model , 2011, The Journal of Neuroscience.
[479] P. Worley,et al. Synphilin-1 associates with α-synuclein and promotes the formation of cytosolic inclusions , 1999, Nature Genetics.
[480] G. Chapman,et al. α-Synuclein overexpression enhances manganese-induced neurotoxicity through the NF-κB-mediated pathway , 2011, Toxicology mechanisms and methods.
[481] S. Gustincich,et al. Inhibition of α-Synuclein Fibrillization by Dopamine Is Mediated by Interactions with Five C-Terminal Residues and with E83 in the NAC Region , 2008, PloS one.
[482] Akihiko Iwai,et al. The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system , 1995, Neuron.
[483] N. Voelcker,et al. Calcium(II) selectively induces α‐synuclein annular oligomers via interaction with the C‐terminal domain , 2004, Protein science : a publication of the Protein Society.
[484] T. Mizutani,et al. Progressive accumulation of ubiquitin and disappearance of α-synuclein epitope in multiple system atrophy-associated glial cytoplasmic inclusions: triple fluorescence study combined with Gallyas-Braak method , 2005, Acta Neuropathologica.
[485] Veerle Baekelandt,et al. The conformation and the aggregation kinetics of α-synuclein depend on the proline residues in its C-terminal region. , 2010, Biochemistry.
[486] R. Clark,et al. Posttranslational protein modifications. , 2005, Critical care medicine.
[487] J. Trojanowski,et al. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. , 2002, Science.
[488] Fabia Febbraro,et al. Co‐expression of C‐terminal truncated alpha‐synuclein enhances full‐length alpha‐synuclein‐induced pathology , 2010, The European journal of neuroscience.
[489] Y. Guillaume,et al. Effect of metals on herbicides–α‐synuclein association: A possible factor in neurodegenerative disease studied by capillary electrophoresis , 2005, Electrophoresis.
[490] D. Eliezer,et al. Conformational properties of alpha-synuclein in its free and lipid-associated states. , 2001, Journal of molecular biology.
[491] Hui-Bie F. Xu,et al. Protective effects of flavonoids in the roots of Scutellaria baicalensis Georgi against hydrogen peroxide-induced oxidative stress in HS-SY5Y cells. , 2001, Pharmacological research.
[492] Gary J. Pielak,et al. Solvent‐induced collapse of α‐synuclein and acid‐denatured cytochrome c , 2001 .
[493] P. Lansbury,et al. Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson’s disease? , 2000, Nature Cell Biology.
[494] K. Ono,et al. β-Synuclein Assembly as a Therapeutic Target of Parkinsons Disease and Related Disorders , 2008 .
[495] Carol D. Hicks,et al. Brain-Permeable Small-Molecule Inhibitors of Hsp90 Prevent α-Synuclein Oligomer Formation and Rescue α-Synuclein-Induced Toxicity , 2010, Journal of Pharmacology and Experimental Therapeutics.
[496] C M Dobson,et al. Designing conditions for in vitro formation of amyloid protofilaments and fibrils. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[497] V. Uversky,et al. Evidence for a Partially Folded Intermediate in α-Synuclein Fibril Formation* , 2001, The Journal of Biological Chemistry.
[498] Min Zhu,et al. Lipid Binding Inhibits α-Synuclein Fibril Formation* , 2003, The Journal of Biological Chemistry.
[499] Y. Engelborghs,et al. Raised calcium promotes α-synuclein aggregate formation , 2011, Molecular and Cellular Neuroscience.
[500] J. Mallet,et al. Rat α‐Synuclein Interacts with Tat Binding Protein 1, a Component of the 26S Proteasomal Complex , 2000 .
[501] J. D. Robertson,et al. Copper, iron and zinc in Alzheimer's disease senile plaques , 1998, Journal of the Neurological Sciences.
[502] T. Iwatsubo,et al. Familial Parkinson Mutant α-Synuclein Causes Dopamine Neuron Dysfunction in Transgenic Caenorhabditis elegans* , 2006, Journal of Biological Chemistry.
[503] Vladimir N Uversky,et al. Intrinsically disordered proteins may escape unwanted interactions via functional misfolding. , 2011, Biochimica et biophysica acta.
[504] M. Farrer,et al. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. , 2004, Annals of neurology.
[505] M. Roy,et al. Facteurs environnementaux dans l'étiologie de la maladie de Parkinson , 1990, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[506] Bharathi,et al. Copper- and iron-induced differential fibril formation in α-synuclein: TEM study , 2007, Neuroscience Letters.
[507] K. Chung,et al. Human Polycomb protein 2 promotes α-synuclein aggregate formation through covalent SUMOylation , 2011, Brain Research.
[508] V. Uversky,et al. Role of individual methionines in the fibrillation of methionine-oxidized α-synuclein , 2004 .
[509] Peter Riederer,et al. Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.
[510] E. Montgomery. Heavy metals and the etiology of Parkinson's disease and other movement disorders. , 1995, Toxicology.
[511] Bruce A. Yankner,et al. Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease , 2002, Nature Medicine.
[512] R. Read,et al. A 2.6 A structure of a serpin polymer and implications for conformational disease. , 1999, Journal of molecular biology.
[513] P. Lansbury,et al. Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. , 2000, Biochemistry.